1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial
1/2 强力霉素治疗艾滋病毒感染者肺气肿:DEPTH 试验
基本信息
- 批准号:10259295
- 负责人:
- 金额:$ 143.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-20 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAge of OnsetAirAlveolar MacrophagesAntibioticsBiologicalBloodBronchoalveolar LavageBronchoalveolar Lavage FluidCarboxyhemoglobinCause of DeathChronic Obstructive Airway DiseaseClinicalConduct Clinical TrialsDataData Coordinating CenterDevelopmentDiagnostic radiologic examinationDiffuseDiseaseDisease ProgressionDouble-Blind MethodDoxycyclineEnrollmentFDA approvedFundingGelatinase AGelatinase BGene ExpressionGeneral PopulationGeneric DrugsHIVHIV InfectionsHIV SeronegativityHealth StatusHemoglobinHigh PrevalenceIncidenceIndividualInterdisciplinary StudyInterventionInvestigationLungMatrix Metalloproteinase InhibitorMatrix MetalloproteinasesMeasuresMetalloproteinase GeneNational Heart, Lung, and Blood InstituteNatural HistoryOralOrganismOxygenParticipantPathogenesisPerformancePharmacy facilityPhasePhase II Clinical TrialsPilot ProjectsPlacebosPopulationPrevalenceProteinsPulmonary EmphysemaQuality of lifeRandomizedReadingRecordsReportingResistanceSafetySamplingSideSiteSmokeSmoking StatusSurveysTestingTimeTissuesTrainingWalkingX-Ray Computed Tomographyantiretroviral therapyarmbarometric pressurebaseclinical careclinical research sitecomorbiditydensitydouble-blind placebo controlled trialeligible participantepidemiologic dataexperienceformer smokerfunctional statusimprovedinnovationinterestlung imagingpatient orientedpatient populationpreventprimary endpointpulmonary functionrandomized placebo controlled trialrespiratorysafety testingsuccesstargeted treatmenttranscriptome sequencingtreatment durationtrend
项目摘要
The DEPTH trial represents an innovative approach to slowing the progression of emphysema in people living
with HIV (PLWH), a population that has accelerated disease progression for which there is no targeted
therapy. We propose a phase II, multi-center, randomized, double-blind, placebo-controlled trial of
doxycycline 100 mg po BID to slow the progression of emphysema as assessed by change in diffusing
capacity (DLCO) among PLWH who are current or former smokers. Eligible participants with emphysema
and well-controlled HIV will be randomized 1:1 to doxycycline or placebo, stratified by smoking status (current
vs former smoker) and clinical site, utilizing dynamic randomization. The primary endpoint of the study is the
rate of decline (slope) of percent predicted DLCO over the 72-week treatment period. We have assembled a
team of experienced clinical sites that has the patient population and expertise to efficiently enroll and conduct
this trial.
In our previous studies, we observed that HIV+ individuals with early emphysema have increased matrix
metalloproteinases (MMP-2, -7, -9, -12; each implicated in emphysema pathogenesis) in bronchoalveolar
lavage (BAL) fluid samples. MMPs are therefore potential targets for intervention aimed at modifying
progression of emphysema specifically in people with HIV. We successfully demonstrated the feasibility of this
approach in our NHLBI-funded single-center randomized, double-blind, placebo-controlled pilot study to test
the safety and tolerability of doxycycline (FDA-approved as an MMP inhibitor to prevent tissue breakdown in
gum disease) over 24 weeks (NCT 01744093). We studied 27 individuals with HIV and COPD/emphysema
randomized 2:1 to doxycycline 100 mg po BID or placebo. In addition to acceptable safety and tolerability,
there were trends toward stabilization of the diffusing capacity (DLCO) and a reduction of BAL fluid MMP-9
activity in participants assigned to the doxycycline arm. The DEPTH trial will extend these promising pilot data
to a formal Phase II clinical trial.
We anticipate that upon completion of this proposed study, our data will support repurposing the inexpensive
antibiotic doxycycline, to slow emphysema progression in PLWH. Specifically we expect to show:
1. Doxycycline slows the progression of emphysema in PLWH, as assessed primarily by DLCO and
secondarily by HRCT.
2. Doxycycline is safe and tolerable when taken orally for 72 weeks in PLWH who have emphysema.
3. Doxycycline improves respiratory quality of life and functional status in PLWH who have emphysema.
DEPTH试验代表了一种创新的方法,可以减缓生活在肺气肿患者的肺气肿进展。
艾滋病毒感染者(PLWH),一个加速疾病进展的人群,
疗法我们提出了一项II期、多中心、随机、双盲、安慰剂对照试验,
多西环素100 mg po BID,以减缓肺气肿的进展,通过弥散指数的变化进行评估
吸烟者的吸烟能力(DLCO)。符合条件的肺气肿受试者
控制良好的HIV将按1:1随机分配至多西环素组或安慰剂组,按吸烟状态分层(目前
与前吸烟者相比)和临床中心,利用动态随机化。研究的主要终点是
72周治疗期间预测DLCO百分比的下降率(斜率)。我们组建了一个
由经验丰富的临床研究中心组成的团队,拥有患者人群和专业知识,可有效招募和开展
这次审判
在我们以前的研究中,我们观察到早期肺气肿的HIV阳性个体,
支气管肺泡上皮细胞中的金属蛋白酶(MMP-2、MMP-7、MMP-9、MMP-12;每种都与肺气肿发病机制有关)
灌洗液(BAL)样品。MMPs因此是旨在修饰的干预的潜在靶点。
肺气肿的进展,特别是在艾滋病毒感染者。我们成功地证明了这一点的可行性
在我们的NHLBI资助的单中心随机,双盲,安慰剂对照的试点研究中,
多西环素(FDA批准的MMP抑制剂,用于预防组织破坏)的安全性和耐受性
牙龈疾病)24周(NCT 01744093)。我们研究了27名艾滋病毒感染者和COPD/肺气肿患者
以2:1的比例随机分配至多西环素100 mg po BID或安慰剂组。除了可接受的安全性和耐受性外,
有弥散量(DLCO)稳定和BAL液MMP-9降低的趋势
DEPTH试验将扩展这些有希望的试点数据,
进入正式的II期临床试验
我们预计,在这项拟议的研究完成后,我们的数据将支持重新利用廉价的
抗生素强力霉素,以减缓肺气肿进展PLWH。具体来说,我们希望展示:
1.多西环素可减缓PLWH患者肺气肿的进展,主要通过DLCO和
其次是HRCT。
2.多西环素口服治疗肺气肿患者72周是安全和耐受的。
3.强力霉素改善肺气肿PLWH患者的呼吸系统生活质量和功能状态。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARSHALL J GLESBY其他文献
MARSHALL J GLESBY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARSHALL J GLESBY', 18)}}的其他基金
1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial
1/2 强力霉素治疗艾滋病毒感染者肺气肿:DEPTH 试验
- 批准号:
10509159 - 财政年份:2021
- 资助金额:
$ 143.29万 - 项目类别:
1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial
1/2 强力霉素治疗艾滋病毒感染者肺气肿:DEPTH 试验
- 批准号:
10703241 - 财政年份:2021
- 资助金额:
$ 143.29万 - 项目类别:
Doxycycline for COPD in HIV-Infected Patients
多西环素治疗 HIV 感染者的慢性阻塞性肺病
- 批准号:
8445031 - 财政年份:2012
- 资助金额:
$ 143.29万 - 项目类别:
Doxycycline for COPD in HIV-Infected Patients
多西环素治疗 HIV 感染者的慢性阻塞性肺病
- 批准号:
8554373 - 财政年份:2012
- 资助金额:
$ 143.29万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 143.29万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 143.29万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 143.29万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 143.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 143.29万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 143.29万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 143.29万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 143.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 143.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 143.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)